Usefulness of Clinical Chemistry Measurements in Classifying Patients with Breast Cancer

References

• Folca P. J., Glascock R. F., Irvine W. T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Lancet 1961; 2: 796
   PubMed Web of Science ®Google Scholar
• Dao T. L. Ablation therapy for hormone dependent tumors. Ann. Rev. Med. 1972; 23: 1
   PubMed Web of Science ®Google Scholar
• McGuire W. L., Horwitz K. B., Pearson O. H., Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977; 39: 2934
   PubMed Web of Science ®Google Scholar
• McGuire W. L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol. 1978; 5: 428
   PubMed Web of Science ®Google Scholar
• Savlov E. D., Wittliff J. L., Hilf R. Further studies of biochemical predictive tests in breast cancer. Cancer 1977; 39: 539
   PubMed Web of Science ®Google Scholar
• Hilf R., Savlov E. D., Rector W. D., Wittliff J. L. Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: a preliminary report. Cancer 1976; 38: 695
   PubMed Web of Science ®Google Scholar
• Hilf R., Wittliff J. L., Rector W. D., et al. Studies on certain cytoplasmic enzymes and specific estrogen receptors in human breast cancer and innonmalignant disease of the breast. Cancer 1973; 33: 2054
   Web of Science ®Google Scholar
• Jakesz R., Kolb R., Reiner G., Chaput B., Schemper M. The relationship between CEA-serum level and CEA-content in tumors of the human breast. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 2: 127
   Google Scholar
• Wahren B., Lidbrink E., Walligren A., Eneroth P., Zajicek J. Carcinoembryonic antigen and other tumor markers in tissue and serum or plasma of patients with primary mammary carcinoma. Cancer 1978; 42: 1870
   PubMed Web of Science ®Google Scholar
• Malmgren R. A., Bennett J. M., Del Vecchio P. R., Dewitt S. H., Feld M., Kazam E., Schneiderman M. A. Evaluation studies of peripheral blood leukocyte changes in malignancy. Acta Cytol 1969; 13: 149
   PubMed Web of Science ®Google Scholar
• McKee L. C. Thromboelastographic distinction of malignant and benign breast masses. South. Med. J 1977; 70: 774
   PubMed Web of Science ®Google Scholar
• Karpas C. M., Dago C., Oppenheim A., Cheng L. Significance of circulating megakaryocytes in the peripheral blood of patients with cancer. Acta Cytol. 1969; 13: 142
   PubMed Web of Science ®Google Scholar
• Houlton O. D. Humoral immunity in human breast cancer: studies involving detection, isolation and characterization of tumor antigen and antitumor antibodies using established tumor cell lines. Diss. Abstr. Int. B 1980; 40: 3087
   Google Scholar
• Müller M., Grossmann H. An antigen in human breast cancer sera related to the murine mammary tumor virus. Nature (London) New Biol. 1972; 237: 116
   PubMedGoogle Scholar
• Grosser N., Thomson D. M. P. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes. Cancer Res. 1975; 35: 2571
   PubMed Web of Science ®Google Scholar
• Tsang P., Tangnavarad K., Perloff M., Lesnick G., Holland J. F., Bekeski J. G. Tumor-associated immunity in breast cancer patients as measured by the 51 leukocyte adherence inhibition assay. J Natl. Cancer Inst. 1980; 5: 372
   Google Scholar
• Anderson J. M., Campbell J. B., Wood S. E., Boyd J. E., Kelly F. Lymphocyte subpopula-tions in mammary cancer after radiotherapy. Clin. Oncol. 1975; 1: 201
   PubMedGoogle Scholar
• Goust J. M., Roof B. S., Fudenberg H. H., O'Brien P. H. T-cell markers in breast cancer patients at diagnosis. Clin. Immunol. Immunopathoi 1979; 12: 396
   PubMedGoogle Scholar
• Blomgren H., Baral E., Perrini B., Wasserman J. Impaired lymphocyte responses to PPD-tuberculin in advanced breast carcinoma. Increased reactivity after depletion of phagocytic or adherent cells. Clin. Oncol 1976; 2: 379
   PubMed Web of Science ®Google Scholar
• Stein J. A., Adler A., Efraim S. B., Maor M. Immunocompetence, immunosuppression, and human breast cancer. Cancer 1976; 38: 1171
   PubMed Web of Science ®Google Scholar
• Whitehead R. H., Bolton P. M., Newcombe R. G., James S. L., Hughes J. E. Lymphocyte response to PHA in breast cancer correlation of predicted prognosis to response to different PHA concentrations. Clin. Oncol. 1975; 1: 191
   PubMedGoogle Scholar
• Ax W. Cell-mediated immunity to tumor-associated antigens detected by in vitro model systems. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 473
   Google Scholar
• Baldwin R. W. In vitro assays of cell-mediated immunity to human solid tumors: problems of quantitation, specificity, and interpretation. J. Natl. Cancer Inst. 1975; 55: 745
   PubMedGoogle Scholar
• Herberman R. B. Cell-mediated immunity to tumor-associated antigens: clinical results. Carcino Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 481
   Google Scholar
• Boehm O. R., Boehm B. J., Humphrey L. J. The natural history of the antibody response to breast antigens. Clin. Exp. Immunol. 1974; 16: 31
   PubMed Web of Science ®Google Scholar
• Humphrey L. J., Estes N. C., Morse P. A., Jewell W. R., Boudet R. A., Hudson J. K. Serum antibody in patients with mammary disease. Cancer 1974; 34: 1516
   PubMed Web of Science ®Google Scholar
• Tsolakidis P. G., Mantz F. A. Serum antibody in patients with breast disease. Ann. Surg. 1974; 180: 124
   PubMed Web of Science ®Google Scholar
• Witkin S. S., Sarkar N. H., Good R. A., Day N. K. An enzyme-linked immunoassay for the detection of antibodies to the mouse mammary tumor virus: application to human breast cancer. J. Immunol. Meth. 1980; 32: 85
   PubMed Web of Science ®Google Scholar
• Barna B. P., Deodhar S. D. Immunology, tumor markers, and breast cancer. Surg. Clin. N. Am. 1978; 58: 693
   PubMed Web of Science ®Google Scholar
• Herberman R. B. Immunodiagnosis and its applicability for cancer screening. Antibiot. Chemother. 1978; 22: 59
   PubMedGoogle Scholar
• Herberman R. B. Overview on new immunologic markers for diagnosis of cancer. Cancer 1978; 42: 1595
   PubMed Web of Science ®Google Scholar
• Herberman R. B. Immunologic approaches to the diagnosis of cancer. Cancer 1976; 37: 549
   PubMed Web of Science ®Google Scholar
• Sloss A. M., Hubay C. A., Powell A. E. Immunologic diagnosis of breast cancer. Surg. Forum 1978; 10: 99
   Google Scholar
• Saracci R., Repetto F. Epidemiology of breast cancer. Semin. Oncol. 1978; 5: 342
   PubMed Web of Science ®Google Scholar
• Donegan W. L., Lewis J. D. Clinical diagnosis and staging of breast cancer. Semin. Oncol. 1978; 5: 373
   PubMed Web of Science ®Google Scholar
• Goerge P., Chalstrey L. J. Factors in the diagnosis of breast disease. Br. J. Surg. 1969; 56: 337
   PubMed Web of Science ®Google Scholar
• Winchester D. P., Sener S. F., et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 1979; 43: 956
   PubMed Web of Science ®Google Scholar
• McGuire W. L., Horwitz K. B., Zava D. T., et al. Hormones in breast cancer – update1978. Metabolism 1978; 27: 487
   PubMed Web of Science ®Google Scholar
• Cho S. Y., Choi H. Y. Causes of death and metastatic patterns in patients with mammary cancer. Am. J. Clin. Pathol. 1980; 73: 232
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Neville A. M. Significance of tumor-index-substances in management. Secondary Spread in Breast Cancer. William Heinemann Medical Books, Chicago 1977; 113
   Google Scholar
• Pomerance W. The cancer-screening dilemma. Postgrad. Med. 1978; 64: 42
   PubMed Web of Science ®Google Scholar
• Davey J. B., Greening W. P., McKinna J. A. Is screening for cancer worthwhile? Results from a well-woman clinic for cancer detection. Br. Med. J. 1970; 3: 696
   PubMed Web of Science ®Google Scholar
• Moskowitz M., Fox S. H. Cost analysis of aggressive breast cancer screening. Radiology 1979; 130: 253
   PubMed Web of Science ®Google Scholar
• Berlin N. I. Programs and plans of the national cancer institute for the research and application of research methods in diagnostics to the diagnosis of cancer. Cancer 1974; 33: 1705
   PubMed Web of Science ®Google Scholar
• Berlin N. I. An overview of research in cancer diagnosis. Mayo Clin. Proc 1975; 50: 249
   PubMed Web of Science ®Google Scholar
• Phillips A. J. Summary of the cancer prevention and detection conference sponsored by the international union against cancer, Sheffield, England. Cancer 1974; 33: 1737
   PubMed Web of Science ®Google Scholar
• Chamberlain J., Rogers P., Price J. L., Ginks S., Nathan B. E., Burn I. Validity of clinical examination and mammography as screening tests for breast cancer. Lancet 1975; 1026
   PubMed Web of Science ®Google Scholar
• Dodd G. D. Present status of thermography, ultrasound arid mammography in breast cancer detection. Cancer 1977; 39: 2796
   PubMed Web of Science ®Google Scholar
• Egan R. L., Goldstein G. T., McSweeney M. M. Conventional mammography, physical examination, thermography and xeroradiography in the detection of breast cancer. Cancer 1977; 39: 1984
   PubMed Web of Science ®Google Scholar
• Hobbs J. R. Laboratory monitoring and screening for cancer. Lancet 1974; 1305
   PubMed Web of Science ®Google Scholar
• Duffy M. J., Hynes N., Groarke Y., Oliver J., O'Broin A., Duffy G. Biochemical markers in breast carcinoma. J., Jr. Med. Assoc 1978; 71: 408
   Google Scholar
• Herberman R. B. Biological markers in breast cancer. Breast Cancer Advances in Research and Treatment. Plenum Press, New York 1978; Vol. 2: 205
   Google Scholar
• McLntire K. R., Masseyef T. R., Breuer H. Measurement of multiple markers in diagnosis and monitoring of therapy. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 517
   Google Scholar
• McLntire K. R. Use of multiple immunoassays for circulating tumor markers. Immunodiagnosis of Cancer. Marcel Dekker, New York 1979; Vol. 9: 521, (Part I)
   Google Scholar
• Neville A. M. Biochemical monitoring of cancer. Ann. Clin. Biochem. 1976; 13: 283
   PubMedGoogle Scholar
• Neville A. M., Williams J., Easty G. C., et al. Products derived from human breast tumors. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 365
   Google Scholar
• Rochman H. Tumor associated markers in clinical diagnosis. Ann. Clin. Lab. Sci. 1978; 8: 167
   PubMed Web of Science ®Google Scholar
• Schwartz M. K. Biochemical and immunochemical markers associated with cancer. Clin. Bull. Sloan-Kettering Inst. 1977; 4: 62
   Google Scholar
• Schwartz M. K., Young D. S. Cancer. Chemical Diagnosis of Disease. Elsevier/North-Holland, New York 1979; 1293
   Google Scholar
• Waalkes T. P., Tormey D. C. Biologic markers and breast cancer. Semin. Oncol. 1978; 5: 434
   PubMed Web of Science ®Google Scholar
• Gold P., Freedman S. O. Demonstration of tumor-specific antigens in human colonic carcino-mata by immunological tolerance and absorption techniques. J. Exper. Med. 1965; 121: 439
   PubMed Web of Science ®Google Scholar
• Gold P., Shuster J., Freedman S. O. Carcinoembryonic antigen (CEA) in clinical medicine. Cancer 1978; 42: 1399
   PubMed Web of Science ®Google Scholar
• Hammarstrom S., Svenberg T., Hedin A., Sunblad G. Antigens related to carcinoembryonic antigen. Scand. J. Immunol. 1968; 7: 35
   Google Scholar
• Shively J. E., Todd C. W. Carcinoembryonic antigen. Scand. J. Immunol. 1978; 7: 19
   PubMed Web of Science ®Google Scholar
• Steward A. M., Nixon D., Zamcheck N., Eisenberg A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 1974; 33: 1246
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Waalkes T. P., Ahmann D., Gehrke C. W., Zumwatt R. W., Snyder J., Hansen H. Biological markers in breast carcinoma. Cancer 1975; 35: 1095
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Waalkes T. P., Snyder J. J., Simon R. M. Biological markers in breast carcinoma – clinical correlations with carcinoembryonic antigen. Cancer 1977; 39: 2397
   PubMed Web of Science ®Google Scholar
• Wang D. Y., Bulbrook R. D., Hayward J. L., Hendrick J. C., Franchimont P. Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer. Eur. J. Cancer 1975; 2: 615
   Google Scholar
• Myers R. E., Sutherland D. J. A., Meakin J. W., Malkin D. G., Kellen J. A., Malkin A. Prognostic value of postoperative blood levels of carcinoembryonic antigen (CEA) in breast cancer. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease. Springer- Verlag, Basel 1979; Vol. 1: 26
   Google Scholar
• Myers R. E., Sutherland D. J., Meakin J. W., Kellen J. A., Malkin D. G., Malkin A. Carcinoembryonic antigen in breast cancer. Cancer 1978; 42: 1520
   PubMed Web of Science ®Google Scholar
• Myers R. E., Sutherland D. H. A., Meakin J. W., Kellen J. A., Malkin A. Prognostic value of postoperative blood levels of carcinoembryonic antigen (CEA) in breast cancer. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 2: 133
   Google Scholar
• Chu T. M., Nemato T. Evaluation of carcinoembryonic antigen in human mammary carcinoma. J. Natl. Cancer Inst. 1973; 51: 1119
   PubMed Web of Science ®Google Scholar
• Haagensen D. E., Kister S. J., Vandevoorde J. P., Gates J. B., Smart E. K., Hansen H. J., Wells S. A. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 1978; 42: 1512
   PubMed Web of Science ®Google Scholar
• Falkson H. C., Van Der Watt J. J., Portugal M. A., Pitout M. J., Falkson G. Carcinoembryonic antigen in patients with breast cancer. Cancer 1978; 42: 1308
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Gazet J. C., Ford H. T., Powles T. J., Nash A. G., McKinna A., Neville A. M. Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet 1980; 296
   PubMed Web of Science ®Google Scholar
• Lokich J. J., Zamcheck N., Lowenstein M. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann. Int. Med. 1978; 89: 902
   PubMed Web of Science ®Google Scholar
• Cove D. H., Woods K. L., Smith C. H., Burnett D., Leonard J., Grieve R. J., Howell A. Tumor markers in breast cancer. Br. J. Cancer 1979; 40: 710
   PubMed Web of Science ®Google Scholar
• Bjöklund B. Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Amibiot. Chemother. 1978; 22: 16
   PubMedGoogle Scholar
• Holyoke D., Chu T. Tissue polypeptide antigen. Carcino-Embryonic Proteins. Elsevier/ North-Holland, New York 1979; Vol. 1: 513
   Google Scholar
• Mattsson W., Borgström S. TPA as a guide in antineoplastic and hormonal treatment of advanced mammary carcinoma. The Folksam Symp. on TPA, Stockholm, November, 13 to 141975
   Google Scholar
• Nemato T., Constantine R., Chu T. M. Human tissue polypeptide antigen in breast cancer. J. Natl. Cancer Inst. 1979; 63: 1347
   PubMedGoogle Scholar
• Silverman L., Dermer G., Tokes Z. Electrophoretic patterns for serum glycoproteins reflect the presence of human breast cancer. Clin. Chem. 1977; 23: 2055
   PubMed Web of Science ®Google Scholar
• Rosato F. Glycoproteins in mammary cancer. Ann. Surg. 1968; 168: 818
   PubMed Web of Science ®Google Scholar
• Rosato F., Seltzer M., Mullen J., Rosato E. Serum fucose in the diagnosis of breast cancer. Cancer 1971; 28: 1575
   PubMed Web of Science ®Google Scholar
• Hadjivassiliou A., Castanaki A., Hristou G., Lissaios B. The diagnostic value of protein bound serum fucose in cancer of the breast. Surg. Gynecol. Obstet. 1975; 140: 239
   PubMedGoogle Scholar
• Waalkes T., Gehrke C., Tormey D., Woo K., Kuo K., Snyder J., Hansen H. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio: comparisons with carcinoembryonic antigen and human chorionic gonadotropin. Cancer 1978; 41: 1871
   PubMed Web of Science ®Google Scholar
• Waalkes T., Mrochek J., Dinsmore S., Tormey D. Serum protein-bound carbohydrates for following the course of disease in patients with metastatic breast carcinoma. J. Natl. Cancer Inst. 1978; 61: 703
   PubMedGoogle Scholar
• Leung J., Bordin G., Nakamura R., DeHeer D., Edgington T. Frequency of association of mammary tumor glycoprotein antigen and other markers with human breast tumors. Cancer Res. 1979; 39: 2057
   PubMed Web of Science ®Google Scholar
• Haagensen D., Mazoujian G., Holder W., Kister S., Wells S. Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann. Surg. 1977; 185: 279
   PubMed Web of Science ®Google Scholar
• Bohn H. Placental and pregnancy proteins. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. I: 290
   Google Scholar
• Searle F., Bagshawe K. D., Leake B. A., Dent J. Serum-SPi-pregnancy-specific-0-glycoprotein in choriocarcinoma and other neoplastic disease. Lancet 1978; 579
   PubMed Web of Science ®Google Scholar
• Wurtz H. Serum concentration of SPi (pregnancy-specific beta 1 glycoprotein) in healthy, nonpregnant individuals, and in patients with non-trophoblastic malignant neoplasms. Arch. Gynaekol 1979; 227: 1
   Google Scholar
• Wurtz H., Geiger W., Grab H., Hoffmann M. Simultaneous assays of SP, (PS/3G), SP3 (α2PAG), CEA, AFP, and β-HCG in the serum of patients with breast cancer and other non-trophoblastic malignancies. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 2: 487
   Google Scholar
• Stimson W. H. Correlation of the blood-level of a pregnancy-associated a-macroglobulin with the clinical course of cancer patients. Lancet 1975; 777
   PubMed Web of Science ®Google Scholar
• Stimson W. H., Anderson J. M., Farquharson D. M. Pregnancy-associated (α1glycoprotein. Lancet 1977; 542
   PubMed Web of Science ®Google Scholar
• Home C. H. W., Rosen S. W. Human placental and pregnancy proteins. Scand. J. Immunol. 1978; 8: 55
   Google Scholar
• Thompson D., Haddow J. Serial monitoring of pregnancy-associated macroglobulin in normal females. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 2: 621
   Google Scholar
• Damber M. G. Pregnancy-associated ^-glycoprotein and cancer. Lancet 1976; 1182
   PubMed Web of Science ®Google Scholar
• Anderson J. M., Gettinby G. Pregnancy-associated macroglobulin (arPAG, PAM) and other detectors of expanding mammary micrometastases. Carcino-Embryonic Proteins. Elsevier/ North-Holland, New York 1979; Vol. 2: 625
   Google Scholar
• Hendrick J. C., Franchimont P. Radio-immunoassay of casein in the serum of normal subjects and of patients with various malignancies. Eur. J. Cancer 1974; 10: 725
   Web of Science ®Google Scholar
• Reddy M. N., Rocbman H., Hunter R. L., Fang V. S., DeMeester T. Carcinoembryonic antigen, k-casein and β-human chorionic gonadotropin in the staging of lung cancer. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 2: 173
   Google Scholar
• Woods K. L., Cove D. H., Morrison J. M., Heath D. A. The investigation of lactalbumin as a possible marker for human breast cancer. Eur. J. Cancer 1979; 15: 47
   Web of Science ®Google Scholar
• Weinberg D. L. Human a-lactalbumin: measurement in serum and in breast cancer organ cultures by radioimmunoassay. Science 1975; 276
   Web of Science ®Google Scholar
• Kithier K., Cejda J., Belamaric J., Al-Sarraf M., Peterson W. D., Vaitkevicius V. K., Poulik M. D. β2-microglobulin: occurrence in fetal life and malignancy. Clin. Chim. Acta 1979; 52: 293
   Google Scholar
• Monsour E. G., Glynn A., Ricanati E. S. Beta-2-microglobulin in early and advanced breast, colon, and lung cancer. ASCO Abstr. 1978; 347
   Google Scholar
• Alpert E., Drysdale J. W. Carcino-fetal human liver ferritins. Nature 1973; 242: 194
   PubMed Web of Science ®Google Scholar
• Drysdale J. Ferritin in cancer: biomedical perspectives. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. I: 249
   Google Scholar
• Giler S., Moroz C. The significance of ferritin in malignant diseases. Biomedicine 1978; 28: 203
   PubMedGoogle Scholar
• Drysdale J., Alpert E. Carcinofetal isoferritins. Scand. J. Immunol 1978; 8: 65
   Google Scholar
• Marcus D., Zinberg N. Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J. Natl. Cancer Inst. 1975; 55: 791
   PubMed Web of Science ®Google Scholar
• Jacobs A., Jones B., Ricketts C., Bulebrook R. D., Wane D. Y. Serum ferritin concentration in early breast cancer. Br. J. Cancer 1976; 34: 286
   PubMed Web of Science ®Google Scholar
• Roberts M. M., Bathgate E. M., Stevenson A. Serum immunoglobulin levels in patients with breast cancer. Cancer 1975; 36: 221
   PubMed Web of Science ®Google Scholar
• Serrou B., Dubois J. B., Robinet-Levy M. IgE serum-levels in cancer patients. Lancet 1975; 396
   Google Scholar
• Haug H., Luthgens M., Schlegel G., Peter G. Cancer testing in a large German hospital with special reference to immunoglobulin E (IgE) and amino acid patterns in cancer patients. Antibiot. Chemother. 1978; 22: 85
   PubMedGoogle Scholar
• Klavfns J. Phase specific proteins in human malignant neoplasms. Ann. Clin. Lab. Sci. 1978; 8: 366
   PubMed Web of Science ®Google Scholar
• Ward A. M., Cooper E. H., Turner R., Anderson J. A., Neville A. M. Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes. Br. J. Cancer 1977; 35: 170
   PubMed Web of Science ®Google Scholar
• Pettingale K. W., Tee D. E. H. Serum protein changes in breast cancer: a prospective study. J. Clin. Pathol. 1977; 30: 1048
   PubMed Web of Science ®Google Scholar
• Bradwell A. R. Haptoglobin and orosomucoid in lung and breast tumours. Immunochem. Clin. Lab. Med 1979; 1: 197
   Google Scholar
• Roberts J. G., Keyset J. W., Btum M. Serum α 1-acid glycoprotein as an index of dissemination in breast cancer. Br. J. Surg. 1975; 62: 816
   PubMed Web of Science ®Google Scholar
• Stolbach L. L., Krant M. J., Fishman W. H. Ectopic production of an alkaline phosphatase isoenzyme in patients with cancer. N. Engl. J. Med 1969; 281: 757
   PubMed Web of Science ®Google Scholar
• Cadeau B. J., Blackstein M. E., Malkin A. Increased incidence of placenta-like alkaline phosphatase activity in breast and genitourinary cancer. Cancer Res. 1974; 34: 729
   PubMed Web of Science ®Google Scholar
• Jacoby B., Bagshawe K. D. A radioimmunoassay for placental-type alkaline phosphatase. Cancer Res. 1972; 32: 2413
   PubMed Web of Science ®Google Scholar
• Wada H. G., Shindelman J. E., Ortmeyer A. E., Sussman H. Demonstration of placental alkaline phosphatase in human breast cancer. Int. J. Cancer 1979; 23: 781
   PubMed Web of Science ®Google Scholar
• Kim N. K., Yasmineh W. G., Feier E. F., Goldman A. I., Theologides A. Value of alkaline phosphatase, 5-nucleotidase, γ-glutamyltransferase, and glutamate dehydrogenase activity measurements, (single and combined) in serum in diagnosis of metastasis to the liver. Clin. Chem. 1977; 23: 2034
   PubMed Web of Science ®Google Scholar
• Tsou K. C., Lo K. W., Tsou W. H., Herberman R. B., Schutt A. Detection of liver metastases with 5′-nucleotide- phosphodiesterase isoenzyme-V in human breast cancer patients. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 429
   Google Scholar
• Weber M. M., Wilson J. R. Serum levels of glycosyltransferases and related glycoproteins as indicators of cancer: biological and clinical implications. CRC Crit. Rev. Clin. Lab. Set 1981; 14: 189
   Google Scholar
• Bosmann H. B., Hall T. C. Enzyme activity in invasive tumors of human breast and colon. Proc. Natl. Acad Sci. U.S.A. 1974; 71: 1833
   PubMed Web of Science ®Google Scholar
• Kessel D., Allen J. Elevated plasma sialyltransferase in the cancer patient. Cancer Res. 1975; 35: 670
   PubMed Web of Science ®Google Scholar
• Henderson M., Kessel D. Alterations in plasma sialyltransferase levels in patients with neoplastic disease. Cancer 1977; 39: 1129
   PubMed Web of Science ®Google Scholar
• Ip C., Dao T. Alterations in serum glycosyltransferases and 5′-nucleotidase in breast cancer patients. Cancer Res. 1978; 38: 723
   PubMed Web of Science ®Google Scholar
• Ganzinger U., Moser K. Sialyltransferase activity: a serum enzyme marker in the follow-up of cancer patients. Recent Results Cancer Res. 1979; 50
   PubMedGoogle Scholar
• Vaitukaitis J. L. Secretion of human chorionic gonadotrophin by tumors. Carcino-Embryonic Proteins. Elsevier/North-Holland, New York 1979; Vol. 1: 447
   Google Scholar
• McArthur J. W. Para-endocrine phenomena in obstetrics and gynecology. Progress in Gynecology. Grune & Stratton, New York 1963; Vol. 4: 146
   Google Scholar
• Vaitukaitis J. L., Braunstein G. D., Ross G. T. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am. J. Obstet. Gynecol. 1972; 113: 751
   PubMed Web of Science ®Google Scholar
• Braunstein G. D., Vaitukaitis J. L., Carbone P. P., Ross G. T. Ectopic production of human chorionic gonadotrophin by neoplasms. Ann. Int. Med. 1973; 78: 39
   PubMed Web of Science ®Google Scholar
• Franchimont P., Zangerle P. F., Hendrick J. C., Reuter A., Colin C. Simultaneous assays of cancer associated antigens in benign and malignant breast diseases. Cancer 1977; 39: 2806
   PubMed Web of Science ®Google Scholar
• Sheth N. A., Saruiya J. N., Ranadive K. J., Sheth A. R. Ectopic production of human chorionic gonadotrophin by human breast tumors. Br. J. Cancer 1974; 30: 566
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Waalkes T. P., Ahmann D., Ghrke C. W., Zumwatt R. W., Snyder J., Hansen H. Biological markers in breast carcinoma. I. Incident of abnormalities of CEA, HCG, three polya-mines, and three minor nucleosides. Cancer 1975; 35: 1095
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Waalkes T. P., Simon R. M. Biological markers in breast carcinoma. II. Clinical correlations with human chorionic gonadotrophin. Cancer 1977; 39: 2391
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Gazet J. C., Ford H. T., Powles T. J., et al. Biochemical markers in human breast cancer. Lancet 1977; 132
   PubMed Web of Science ®Google Scholar
• Home C. H. W., Reid I. N., Milne G. D. Prognostic significance of inappropriate production of pregnancy proteins by breast cancer. Lancet 1976; 2: 279
   PubMed Web of Science ®Google Scholar
• Castro A., Buschbaum P., et al. Ectopic human chorionic gonadotrophin in breast carcinoma. Experiemia 1979; 15: 1392
   Google Scholar
• Austin L. A., Heath H. Calcitonin: physiology and pathophysiology. N. Engl. J. Med. 1981; 304: 269
   PubMed Web of Science ®Google Scholar
• Schwartz K. E., Wolfsen A. R., Forster B., Odell W. D. Calcitonin in nonthyroidal cancer. J. Clin. Endocrinol. Metab. 1979; 49: 438
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Greenberg P. D., Hillyard C., Maclntyre I. Plasma-immunoreactive-calci-tonin in patients with non-thyroid tumours. Lancet 1974; 1080
   PubMed Web of Science ®Google Scholar
• Coombes R. C., Easty G. C., Detre S. I., et al. Secretion of immunoreactive calcitonin by human breast carcinomas. Br. Med. J. 1975; 4: 197
   PubMed Web of Science ®Google Scholar
• Silva O. L., Becker K. L. High plasma calcitonin levels in breast cancer. Br. Med. J. 1976; 2: 460
   Google Scholar
• Coombes R. C., Gazet J. C., Sloane J. P., et al. Biochemical markers in human breast cancer. Lancet 1977; 132
   PubMed Web of Science ®Google Scholar
• Hillyard C. J., Coombes R. C., Greenberg P. B., et al. Calcitonin in breast and lung cancer. Clin. Endocrinol. 1976; 5: 1
   PubMed Web of Science ®Google Scholar
• Russell D. H. Increased polyamine concentrations in the urine of human cancer patients. Nature (London) New Biol. 1971; 233: 144
   PubMedGoogle Scholar
• Russell D. H., Durie B., Salmon S. E. Polyamines as predictors of success and failure in cancer chemotherapy. Lancet 1975; 797
   PubMed Web of Science ®Google Scholar
• Chaisiri P., Harper M. E., et al. Plasma spermidine concentrations in patients with tumors of the breast or prostate or testes. Clin. Chim. Acta 1980; 104: 367
   PubMed Web of Science ®Google Scholar
• Cushieri A. Urinary hydroxyproline excretion in early and advanced breast cancer: a sequential study. Br. J. Surg. 1973; 60: 800
   PubMed Web of Science ®Google Scholar
• Guzzo C. E., Pachas W. N., Pinals R. S., Krant M. J. Urinary hydroxyproline excretion in patients with cancer. Cancer 1969; 24: 382
   PubMed Web of Science ®Google Scholar
• Cushieri A., Felgate R. A. Urinary hydroxyproline excretion in carcinoma of the breast. Br. J. Exp. Pathol 1972; 53: 237
   PubMedGoogle Scholar
• Cushieri A. Urinary hydroxyproline excretion and survival in cancer of the breast. Clin. Oncol. 1975; 1: 127
   PubMedGoogle Scholar
• Powles T. J., Leese C. L., Bondy P. K. Hydroxyproline excretion in patients with breast cancer and response to treatment. Br. Med. J. 1975; 2: 164
   PubMed Web of Science ®Google Scholar
• Powles T. J., Rosset G., Leese C. L., Bondy P. K. Early morning hydroxyproline excretion in patients with breast cancer. Cancer 1976; 38: 2564
   PubMed Web of Science ®Google Scholar
• Gasser A. B., DePierre D., Alberto P., Courvoisier B. Study of hydrosyproline in the diagnosis of bone metastases from cancer of the breast. Schweiz Med. Wschr. 1977; 107: 984
   PubMedGoogle Scholar
• Gasser A. B., DePierre D., Courvoisier B. Total urinary and free serum hydroxyproline in metastatic bone disease. Br. J. Cancer 1979; 39: 280
   PubMed Web of Science ®Google Scholar
• Franchimont P., Zangerle P. F., et al. Simultaneous assays of cancer-associated antigens in benign and malignant breast diseases. Breast 1977; 3: 5
   Google Scholar
• Franchimont P., Zangerle P. F., et al. Simultaneous assays of cancer-associated antigens in various neoplastic disorders. Cancer 1976; 38: 2287
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Waalkes T. P., Snyder J. J., Simon R. M. Biological markers in breast carcinoma. III. Clinical correlations with carcino-embryonic antigen. Cancer 1977; 39: 2397
   PubMed Web of Science ®Google Scholar
• Woo K. B., Waalkes T. P., et al. A quantitative approach to determining disease response during therapy using multiple biologic markers. Cancer 1978; 41: 1685
   PubMed Web of Science ®Google Scholar
• Winkel P., Statland B. E., Moridsen H., Sheike O., Bentzon M. W., in review
   Google Scholar